Drug Discovery World
SEPTEMBER 1, 2022
Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .
XTalks
DECEMBER 12, 2023
Our pipeline, for example, includes a new class of recombinant antibodies. Right now, they are doing what is probably the most advanced work in the field of polyclonal recombinant antibody therapies. The science is brilliant.
Drug Discovery World
NOVEMBER 9, 2023
The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Ioanna Stamati, PhD, Team Leader, Bioconjugation, Antikor Biopharma, on: ‘Antibody fragment drug-conjugates (FDCs): Analysing novel formats with high DAR’.
Expert insights. Personalized for you.
52 
Let's personalize your content